2013 – Page 19 – Oral Cancer News

Chicago ENT head and neck surgeons using VELscope Vx to enhance oral cancer surgery success rate

Source: www.menafn.com Author: press release LED Medical Diagnostics Inc. subsidiary LEDDental announced today that its VELscope Vx enhanced oral assessmentdevice will now be used by Chicago Otolaryngology Associates for oralmucosal abnormality assessment and when performing surgery on oral cancer patients. According to Chicago Otolaryngology Associates' Howard Kotler, MD,FACS, "We pride ourselves on embracing state-of-the-art technologies that allow us to provide the best patient care possible. The VELscopeVx may significantly enhance our ability to see the entire cancerous or precancerous lesion that needs to be excised, allowing us to minimize risk of additional unnecessary surgery." The VELscope Vx's fluorescence visualization technology is the first approved by the FDA and Health Canada to help surgeons determine the surgical margins when excising cancerous and precancerous tissues. The technology is also approved to help dental and medical professionals discover cancerous and precancerous tissue that might not be apparent to the unaided eye. The vast majority of the nearly 12,000 VELscope devices in use around the world are used by dental practices. Typically, when a suspicious lesion is detected by a dentist, the patient is referred to an oral surgeon or a periodontist for a surgical biopsy, which is then evaluated by an oral pathologist. If the biopsy sample is determined to be cancerous or precancerous, the patient is usually referred to an ENT head and neck surgeon for consultation and likely excision. VELscope technology was developed to address the problem of detecting all abnormal tissue, including that beneath the surface, as well as making [...]

Oral Cancer Foundation News Team - A2013-01-10T09:25:49-07:00January, 2013|Oral Cancer News|

Another Side Effect Of Chemotherapy: ‘Chemo Brain’

Source: NPR Date: December 28, 2012 Author: Patti Neighmond It's well-known that chemotherapy often comes with side effects like fatigue, hair loss and extreme nausea. What's less well-known is how the cancer treatment affects crucial brain functions, like speech and cognition. For Yolanda Hunter, a 41-year-old hospice nurse, mother of three and breast cancer patient, these cognitive side effects of chemotherapy were hard to miss. "I could think of words I wanted to say," Hunter says. "I knew what I wanted to say. ... There was a disconnect from my brain to my mouth." Before getting treated for cancer, Hunter led a busy, active lifestyle. But the effects of chemotherapy on her brain made it difficult for her to do even the most basic things. "I couldn't even formulate a smile. I had no expression," she says. "I might feel things on the inside, but it didn't translate to the outside. ... It literally felt like you were trying to fight your way through fog." Some cancer patients call this mental fog "chemo brain." And now researchers are trying to quantify exactly what chemo brain really is. Oncologist Jame Abraham, a professor at West Virginia University, says about a quarter of patients undergoing chemotherapy have trouble processing numbers, using short-term memory and focusing their attention. Using positron emission tomography, or PET, scans to measure blood flow and brain activity, Abraham looked at the brains of 128 breast cancer patients before they started chemotherapy and then again, six months later. On [...]

Charlotte Parker2013-01-10T13:00:01-07:00January, 2013|Oral Cancer News|

DNA adducts linked to oral cancer in smokers

Source: www.news-medical.net Author: Sarah Guy, medwireNews Reporter Having a high susceptibility to certain types of DNA damage caused by tobacco smoking could significantly increase the risk for oral cancer, show results of a Taiwanese study. Levels of BaP 7,8-diol 9,10-epoxide (BPDE) - a metabolite of Benzo[a]pyrene, an important carcinogen found in cigarette smoke - correlated positively with smoking status in a cohort of individuals with oral cancer, report the researchers. The findings also indicate a significantly increased risk for oral cancer among individuals with high DNA adduct levels compared with their peers with low levels. "Based on our finding, we suggest that detected BPDE-like DNA adducts could be used as a biomarker for oral cancer risk," write Huei Lee (Taipei Medical University) and colleagues in the Archives of Oral Biology. The team analyzed BPDE-DNA adduct levels in oral tissue samples from 158 oral cancer patients and 64 individuals without cancer (controls), using immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). The results of these assays significantly and positively correlated , so that immunohistochemistry-negative patients did not have detectable DNA adduct levels using ELISA and vice versa. DNA adduct levels also positively correlated with smoking status among the cancer patients, note the researchers, with significantly higher adduct levels among smokers than nonsmokers, at 93.18 versus 0.04 adducts per 108 nucleotides. Lee and co-workers also observed that cancer patients had significantly higher DNA adduct levels than controls, at a range of 0-358.00 versus 0-39.50 adducts per 108 nucleotides. Indeed, DNA adduct level was an [...]

Oral Cancer Foundation News Team - A2013-01-05T15:32:56-07:00January, 2013|Oral Cancer News|